Our Pipeline

Our research is focused in the areas of inflammation and immunology, and our pipeline of internally discovered programs is targeted to address significant patient needs.

 


Key Programs


We apply insights and innovation at each stage of our business and utilize our internal capabilities and those of our partners around the world. The table below summarizes the status of our key programs for internal development or co-development.

Ampreloxetine
(TD-9855)
FULLY OWNED
Neurogenic
orthostatic
hypotension
(nOH)
Phase 3
TD-1473
gut-selective
JAK inhibitor
PARTNER: logo
Ulcerative
colitis
Phase 2b/3
Crohn's
disease
Phase 2
TD-8236
lung-selective
JAK inhibitor
FULLY OWNED
Asthma
Phase 1
TD-5202
gut-selective
irreversible
JAK3 inhibitor
PARTNER: logo
Inflammatory
intestinal diseases
Phase 1
New
Organ-Selective
Projects
FULLY OWNED
Various
indications
Research

Economic Interests

We have an economic interest in potential future payments from GSK pursuant to its agreements with Innoviva, Inc. relating to certain respiratory programs, plus certain other programs that have been out-licensed or divested which do not require further economic investment by Theravance Biopharma.

Economic interests in GSK respiratory programs*
Trelegy
Ellipta
(FF/UMEC/VI)

GSK
COPD
Approved
Asthma
Filed
Outlicensed or divested programs
Vibativ
(Telavancin)
PARTNER: logo
cSSSI,
HABP/VABP,
concurrent
bacteremia
Approved
Velusetrag
PARTNER: logo
Gastroparesis
Phase 2
TD-8954
(TAK-954)
PARTNER: logo
Post-operative
Gastrointestinal
Dysfunction (POGD), IV
Phase 2
*The information regarding the Trelegy Ellipta programs is based solely upon publicly available information and may not reflect the most recent developments under the programs.

Glossary

COPD
Chronic Obstructive Pulmonary Disease

cSSSI
Complicated Skin and Skin Structure Infections

FF
Fluticasone Furoate

HABP/VABP
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

IV
Intravenous

JAK inhibitor
Janus kinase inhibitor

nOH
Neurogenic Orthostatic Hypotension

POGD
Post-operative Gastrointestinal Dysfunction

UMEC
Umeclidinium

VI
Vilanterol

STATUS
The most advanced stage of clinical development that has been completed or is in process

PHASE 1 
Initial clinical safety testing into patients or healthy human volunteers, or studies directed toward understanding the mechanisms of action of the drug

PHASE 2
Further clinical safety testing and preliminary efficacy testing in a limited patient population

PHASE 3
Evaluation of clinical efficacy and safety within an expanded patient population

FILED
A marketing application has been submitted to a regulatory authority

APPROVED
Approved for marketing in one or more countries